Dr. Patrick Hwu speaks with Dr. Drew Pardoll, a pioneering leader in tumor immunology and director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins. Dr. Pardoll reflects on his early path into immunology and the scientific discoveries that helped establish immunotherapy as a transformative approach to cancer treatment. The conversation explores how tumors suppress immune responses within the tumor microenvironment and how understanding these immune “brakes” led to the development of immune checkpoint inhibitors, including anti–PD-1 therapies.
Dr. Pardoll discusses the importance of learning from early clinical failures, the promise of combination therapies, and advances in engineered T cells. Looking ahead, the episode highlights emerging technologies such as single-cell analysis and artificial intelligence, which are accelerating discoveries across cancer research and beyond. Dr. Pardoll also shares insights on mentorship, collaboration, and the importance of sustained investment in science to continue reducing cancer mortality.
What You’ll Learn from Dr. Pardoll
How early clinical observations from bone marrow transplantation helped reveal the curative potential of T-cell–mediated anti-tumor immunity
Why many early cancer vaccines failed clinically, and how those failures directly led to the discovery of immune checkpoint pathways
The critical role of the tumor microenvironment in suppressing effective immune responses, even when tumor-specific T cells are present
Why combination therapies (immunotherapy + chemotherapy, targeted therapy, or cell therapy) are essential to overcoming tumor escape and resistance
Emerging advances in engineered adoptive cell therapies, including logic-gated T cells designed for improved specificity and safety
How single-cell and spatial transcriptomic technologies are transforming our ability to dissect the tumor ecosystem
The growing role of AI in analyzing massive immunologic datasets and accelerating discovery
